BIAL and Medis, d.o.o. announce that they have entered an exclusive partnership on two BIAL's proprietary drugs: eslicarbazepine acetate and opicapone.
The established partnership comprises an exclusive distribution agreement for eslicarbazepine acetate in the Czech Republic and Slovakia and an exclusive distribution agreement for opicapone in 12 CEE countries (Bosnia and Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, North Macedonia, Serbia, Slovakia, and Slovenia.)
“We are pleased to have Medis as our new partner. We believe this partnership is another important step for the extensive commercialisation of our innovative medicines. Medis shares our long-term vision and we look forward to bringing these important treatment options to patients in the CEE region,” said António Portela, Chief Executive Officer of BIAL.
“In Medis we are excited and proud to partner with BIAL and thus being able to provide two medicines which we firmly believe represent a much-needed relief to thousands of people in the region who suffer from Parkinson’s disease and epilepsy.” claimed Martina Perharic, Medis’ Chief Executive Officer.
Epilepsy has a high prevalence with 6 million people affected in Europe and 15 million Europeans estimated to experience a seizure at some time in their life.1
Parkinson's disease is a chronic, progressive neurodegenerative disorder characterized by a strong reduction of the neurotransmitter dopamine, caused by the degeneration of certain neurons in the brain. The European Parkinson's Disease Association (EPDA) estimates that approximately 1.2 million people in Europe suffer from this disease.
1- Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe. WHO report. Available at https://www.who.int/mental_health/neurology/epilepsy/euro_report.pdf. Last Accessed in June 2021